Drug Prices
-
Caught my eye — 5/17/24
Read more: Caught my eye — 5/17/24Crab cakes and … horse racing. That’s what Maryland does. Mine will come with a side of Smith Island cake which I’m making tomorrow morning. Wish me luck. Odds aren’t stacked. The Centers for Medicare & Medicaid Services (CMS) announced that the Medicaid rule won’t contain the stacking provision. A little odd to pre-announce it,…
-
340B, Caught my eye, Drug Prices, Employers, Healthcare Costs, ICER, Inflation Reduction Act, Medicare Negotiation, Medicare Part D, Medicare Transaction Facilitator, Reference Pricing, ValueCaught my eye — 5/10/24
Read more: Caught my eye — 5/10/24Back to back. Arnold Ventures put out the latest anti-pharma talking points (h/t Brian Reid) and here were two back to back – Here’s the problem, it really isn’t about the cost of drugs. I mean you could take that drug price and reduce it 98% and the 25% cost share would still be too…
-
Caught my eye — 5/3/24
Read more: Caught my eye — 5/3/24LDT. Not a sandwich, not a drink but laboratory developed tests. On Monday, the Food and Drug Administration (FDA) put out the long anticipated final rule on LDTs. If you’re more of a prescription drug policy person, get used to following LDT policy. We’ve moved from tests that are nice but, even if you have…
-
Caught my eye — 4/26/24
Read more: Caught my eye — 4/26/24What the math. Yesterday afternoon CMS released a technical memo on the changes to True Out-of-Pocket (TrOOP) Costs and the maximum monthly cap for the Medicare prescription payment plan (MP3.) Simply put, they put out a memo that shows the math for the smoothing program. I need to work through some of the examples because,…
-
Return of the MAC (Well I tried to tell you so)
Read more: Return of the MAC (Well I tried to tell you so)Last week MedPAC, the Medicare advisory committee to Congress, had a really interesting session on generic drug pricing in the Medicare prescription drug program (Part D.) There is always so much focus on branded drugs that an opportunity to flip the script and learn about the 90% of prescription drug utilization in Part D (and…
-
Biosimilars, Caught my eye, CMMI, Drug Prices, Drug shortages, Health Equity, Inflation Reduction Act, Medicare Part D, ObesityCaught my eye — 4/5/24
Read more: Caught my eye — 4/5/24Ruling It. Yesterday afternoon, the Centers for Medicare & Medicaid Services released the MA/Part D final rule. Personally, most of it was not up my alley but I did read over the changes to the changes to an approved formulary sections. In December 2022, CMS proposed allowing immediate substitution of interchangeable biosimilars or branded biologics…
-
Caught my eye — 3/29/24
Read more: Caught my eye — 3/29/24It has been a week of odds and ends so if you’re catching up after ignoring your emails, you didn’t miss a ton. Honestly, it seems like a good time to be a DC law firm working on pharmaceutical issues. You have the usual Inflation Reduction Act submissions, comment letters (which, for what it is…
-
Caught my eye — 3/8/24
Read more: Caught my eye — 3/8/24Happy International Women’s Day. Best display of International Women’s day I’ve ever seen was in Russia when I was studying abroad. They took it SERIOUSLY. Not just a LinkedIn Holiday. Cat-astrophe? No, just a political speech – not reality. President Biden talked about increasing the number of negotiated drugs up to 50 a year. Not…
-
Biosimilars, Caught my eye, Drug Prices, Healthcare Costs, Medicare Advantage, Medicare Part D, Pharmacy Benefit Managers, ValueCaught my eye — 2/9/24
Read more: Caught my eye — 2/9/24A whirlwind of a week. I regrouped on Wednesday and got a run in and some pottery wheel time and then it all fell apart again (in a good way) on Thursday where I forgot to leave my desk for hours and hours. One of those “I love working” and forget time exists. So much…
-
Caught my eye, CMMI, Drug Prices, Inflation Reduction Act, Insulin, Medicare Negotiation, State-based ReformCaught my eye — 2/2/24
Read more: Caught my eye — 2/2/24It is a dumb bucket list thing but one day I will go experience the Groundhog Day festivities. Dream big, I know. Cell and Gene Update. This week the Centers for Medicare and Medicaid Innovation (CMMI) released the Cell and Gene Therapy (CGT) Access model which will initially focus on sickle cell disease. It is…
Latest news
- Caught my eye — 11/15/24
- Caught my eye — 11/8/24
- Caught my eye — 11/1/24
- Caught my eye — 10/25/24
- Caught my eye — 10/18/24
Categories
- 340B (26)
- Affordable Care Act (3)
- Alzheimer's (4)
- Biosimilars (18)
- Caught my eye (46)
- Chevron Deference (2)
- CMMI (8)
- Copay Accumulators (6)
- COVID (2)
- Drug Prices (23)
- Drug shortages (7)
- DTC (2)
- Employers (7)
- Generics (3)
- Health Equity (3)
- Healthcare Costs (21)
- ICER (5)
- Importation (2)
- Inflation Reduction Act (39)
- Insulin (4)
- IP (3)
- Long term care (1)
- Medicaid (3)
- Medicare Advantage (12)
- Medicare Negotiation (40)
- Medicare Part D (35)
- Medicare Transaction Facilitator (2)
- Medicare Transaction Facilitator (6)
- Obesity (18)
- On the Horizon (1)
- Orphan Drugs (2)
- Pharmacy Benefit Managers (23)
- Reference Pricing (3)
- State-based Reform (13)
- Uncategorized (4)
- Utilization Management (1)
- Vaccines (2)
- Value (7)